Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study
{{output}}
While third-generation EGFR tyrosine kinase inhibitors (TKIs) improve outcomes in EGFR-mutant NSCLC, optimal selection between these agents remains uncertain. This real-world study compares the efficacy and safety of aumolertinib with those of osimertinib in t... ...
